COMPANY

Dren Bio

HQ: San Carlos, CA source · drenbio.com ↗ · West Coast

Keywords: bispecific antibody oncology neurology immunology Aplastic Anemias Severe Aplastic Anemia Relapse Severe Aplastic Anemia Refractory Severe Aplastic Anemia Non-severe Aplastic Anemia Alopecia Areata Vitiligo LGLL - Large Granular Lymphocytic Leukemia Primary Cutaneous Gamma-Delta T-Cell Lymphoma Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma Hepatosplenic T-cell Lymphoma Subcutaneous Panniculitis-Like T-Cell Lymphoma Aggressive NK Cell Leukemia Hydroa Vacciniforme-Like Lymphoproliferative Disorder Nasal Type Extranodal NK/T Cell Lymphoma Enteropathy-Associated T-Cell Lymphoma Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma Cytotoxic PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker) Cutaneous PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker) Triple Negative Breast Cancer HER2-negative Breast Cancer Non Small Cell Lung Cancer Cervical Cancer Castrate Resistant Prostate Cancer Pancreatic Ductal Adenocarcinoma Head-and-neck Squamous Cell Carcinoma Endometrial Cancer Ovarian Cancer Gastric Cancer Gastroesophageal-junction Cancer Urothelial Carcinoma DR-01 Dibotatug (DR-01) Dibotatug DR-0202 DR-0201

Location: San Carlos, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

7Trials (company is sponsor)

Timeline

2026-08 Trial start 1: A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes source ↗
Jun 3, 2025 Trial start Phase 1: A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas source ↗
Mar 3, 2025 Trial start Phase 1: A Study of Subcutaneous DR-01 in Healthy Volunteers source ↗
Oct 30, 2024 Trial start Phase 1: A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo source ↗
Nov 26, 2023 Trial start Phase 1: A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DR-0201 in Healthy Adult Volunteers source ↗
Jul 13, 2022 Trial start Phase 1/Phase 2: A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas source ↗

Upcoming milestones

2026-12 (ESTIMATED) · Phase 1/Phase 2 · A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas · NCT05475925
2027-05 (ESTIMATED) · Phase 1 · A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo · NCT06602232
2027-07 (ESTIMATED) · Phase 1 · A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas · NCT06999187
2029-04 (ESTIMATED) · 1 · A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes · NCT07712562

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 7

Record	Title	Phase	Status	Start	Primary completion
NCT07712562	A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes	1	Not yet recruiting	2026-08	2029-04 (estimated)
NCT06602232	A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo	Phase 1	Active, not recruiting	Oct 30, 2024	2027-05 (estimated)
NCT05475925	A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas	Phase 1/Phase 2	Recruiting	Jul 13, 2022	2026-12 (estimated)
NCT07647627	Availability of Dibotatug (DR-01) Outside Clinical Trials Via Expanded Access for Eligible Participants	Not listed	Available	Not listed	Not listed
NCT06999187	A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas	Phase 1	Recruiting	Jun 3, 2025	2027-07 (estimated)
NCT06766864	A Study of Subcutaneous DR-01 in Healthy Volunteers	Phase 1	Completed	Mar 3, 2025	Aug 27, 2025 (actual)
NCT06008652	A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DR-0201 in Healthy Adult Volunteers	Phase 1	Completed	Nov 26, 2023	Jul 24, 2024 (actual)